MEET THE PEOPLE BEHIND PHYLOGICA

Board

Board

  • Stephanie Unwin, LLB, B Econ, GAICD
  • Robert Hayes, PhD
  • Bernard Hockings, RFD, MD, MBBS, FRACP, FCSANZ, GAICD
  • Sahm Nasseri, BChemEng (Hons), MBA
  • Michael Williams, BA (Hons) Education

 

Stephanie Unwin, LLB, B Econ, GAICD | Chief Executive Officer & Managing Director

Stephanie Unwin brings extensive senior executive and commercial experience to PYC. Since becoming an executive general manager in 2011, Stephanie has held positions of increasing responsibility, including Head of Strategy and Innovation; Chief Transformation Officer; and General Manager of both Commercial and Retail Business Units within the $3bn electricity utility.

Ms. Unwin’s experiences range across operational and commercial topics, including managing the retail P&L and an internal team of over 150 people, presiding over multiple complex commercial transactions, including the merger of Verve Energy and Synergy. She also has substantial experience as a company Director with over 15 years of Board engagements across both ASX and TSX including a Non-Executive Director role overseeing the growth of Alacer Gold from a junior ASX listed entity to a $2bn dual listed company at its height.

She holds a Bachelor degrees in Law and Economics from Murdoch University and has completed an Advanced Management Program (191) at Harvard Business School in 2016.

Robert Hayes, PhD | Executive Director

Dr Hayes was previously Head of Biologics at multinational biopharmaceutical company Amgen (NASDAQ:AMGN), responsible for the leadership, strategic direction and operational management of the company’s biologics preclinical discovery and biotherapeutics pipeline. This included bioreagent generation, large molecule lead identification, biologics optimization, and the transition to upstream process development and manufacturing.

Prior to Amgen, Dr Hayes spent seven years as Vice President & Venture Leader of a biotech company within Janssen R&D that focused on developing and exploiting small alternative scaffold proteins. He was also a Senior Director of Protein Engineering at Johnson and Johnson, one of the worlds’ largest healthcare companies, for over three years.

With over 20 years’ experience in biotech start-ups and large pharmaceutical companies, Dr Hayes has a proven track record in building teams around new scientific ideas and technologies. He also has significant experience in forming partnerships between biotech companies and university partners to advance the development and application of novel therapeutic platforms.

Dr Hayes holds a Ph.D. from the Imperial College London, where he was the Royal College of Science Scholar and a Royal Society University Research Fellow. He also completed postdoctoral research at Imperial and University California at Berkeley.

Bernard Hockings RFD, MD, MBBS, FRACP, FCSANZ, GAICD | Non-Executive Director

Dr Hockings was previously an interventional cardiologist and Clinical Associate Professor in Medicine at the University of Western Australia. Past appointments have included Director of the Coronary Care Unit at Royal Perth Hospital, Chair of the Medical Advisory Committee Mount Hospital, Director of the Cardiac Catheterisation Laboratory St John of God Hospital Bunbury and Director of Health Reserves (WA) for the Royal Australian Air Force. Dr Hockings has previously served on the board of the WA branch of the National Heart Foundation.

Dr Hockings has a lifelong interest in medical research. His doctoral thesis concerned vasodilator therapy in the treatment of heart failure.

Dr Hockings is a major shareholder in Phylogica.

Sahm Nasseri, BChemEng (Hons), MBA | Non-Executive Director

Mr Nasseri is currently a Director in Global Strategy and marketing of HPV Vaccines at Merck &Co based in New York, USA. He started at Merck in the Australian subsidiary where he was Strategy and Business  Development lead, reporting to the Managing Director and sitting on the local country leadership team.

Prior to joining Merck, Sahm was a management consultant with McKinsey & Company based in the Sydney office. During his 4 years at McKinsey, Sahm was involved in leading Strategy and Operations programs across several clients in healthcare, pharma, telecommunications, retail and mining. He has broad strategy, marketing, commercial deal-making and policy experience in the healthcare space across Asia Pacific and the US.

Sahm holds an MBA through a combined program at Columbia University in New York and the London Business School and has a Bachelors in Chemical Engineering (Hons) from the University of New South Wales.